In recent months, the world has seen unprecedented investment in new vaccines. Yet, while a COVID-19 vaccine proven to be safe and effective may be less than a year away, a new tuberculosis vaccine might only be ready to be rolled out in a decade, despite a massive head start over COVID-19. Amy Green takes a closer look at the race for a new vaccine for the world’s top infectious disease killer.
A recent global online survey suggests that more than a third of South Africans would not want a COVID-19 vaccine if and when it becomes available. Adele Baleta reports on vaccine hesitancy in South Africa.
South Africa is consolidating its place in the race for a COVID-19 vaccine with its participation starting from next month in two new international trials of vaccine candidates. Adele Baleta reports.
Immunity to COVID-19 is much more interesting and much more complicated than simply something you do or do not have. Kathryn Cleary spoke to two experts about what we know about COVID-19 immunity and the implications of that for antibody testing and the development of vaccines.
Timothy Lebelwane of Diepsloot is one of 2 000 people in South Africa participating in a COVID-19 vaccine trial spearheaded by Wits University. Biénne Huisman spoke to him about life as a participant in such an important vaccine trial.
It seems HIV and TB are falling by the wayside in the drive to stop the spread of COVID-19. Where we can we must minimise the harm to the HIV and TB response, and we need to see the opportunity to address all three diseases together, writes Erica Penfold.
This is the fourth issue of COVID-19 Report. We point you to the latest quality science on the pandemic. If you come across unfamiliar terms, there is a glossary at the bottom of the article.
People in South Africa who have recovered from COVID-19 are donating their blood to help others who are trying to fight off the disease that has so far claimed over 200 lives and infected over 10 000 people in the country.